突变型P53与MDR在膀胱移行细胞癌中表达的意义

Significance of expression of mutant P53 and MDR in bladder transitional cell carcinoma

目的探讨膀胱移行细胞癌(BTCC)中MDR的表达产物P-gp及P53表达的意义。方法利用免疫组织化学链霉菌素-生物素(S-P)法测83例BTCC的P-gp和P53的表达。结果在83例膀胱移行细胞癌中P-gp阳性表达率为71%,P53阳性表达率为51%;P-gp阳性表达在病理分级、临床分期及预后中差异无统计学意义(P>0.05);P53随着病理分级和临床分期而增高,差异均有统计学意义(P<0.05);P53阳性表达复发组高于无复发组(P<0.01)。结论检测P-gp可指导BTCC的化疗药物选择,P53高表达与BTCC的进展有关,P-gp、P53高表达者预后及疗效差,P53可作为BTCC独立的预后因素。

Objective To explore the significance of expression of P-gp and mutant p53 in bladder transitional cell carcinoma. Methods The expression of P-gp and p53 gene in specimens of 83 cases of patients with bladder transitional cell carcinoma were studied by immunohistochemical method. Results The positive expression rate of P-gp gene and mutant p53 gene was 71% and 51% respectively in specimens of 83 cases. The level of P-gp has no significantly statistical difference with the tumor pathological grade, clinical stage and prognosis （P 〉0.05）. The expression of 1053 was higher in high grade tumors. It had a significantly statistical difference （P〈0.05）. The mutant p53 positive rates were higher in recurrent patients （P〈0.01）. Conclusion To examine P-gp is beneficial to selection of bladder carcinoma chemotherapeutic medicines. The mutant p53 gene may be involved in tumor progression in urotholied neoplasis. Overexpression of P-gp and mutant p53 of the tumors suggests that the patients have a worse prognosis and poor reaction to the therapy. The mutant p53 gene could be taken as an independent prognostic factor for tumor progression in BTCC.